Welcome to our dedicated page for NOVO NORDISK A S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk A/S held its Annual General Meeting, where shareholders approved the statutory Annual Report 2025 and the distribution of profits. The total dividend for 2025 was set at DKK 11.70 per A and B share, consisting of an interim dividend of DKK 3.75 already paid in August 2025 and a final dividend of DKK 7.95 to be paid in March 2026.
Shareholders re-elected Cees de Jong as vice chair and several existing board members, and elected Helena Saxon, Jan van de Winkel and Ramona Sequeira to the Board. Deloitte was re-appointed as auditor.
The Board received authorisation until the 2027 AGM to repurchase up to 10% of the share capital, subject to a 10% holding limit, and an extension to increase share capital until 1 April 2028 by up to nominally DKK 44,650,000. Committee compositions were updated, and Poul Weihrauch will join as a Board observer with the intention of nomination in 2027.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 3.8 billion running from 4 February 2026 to 4 May 2026.
As of 20 March 2026, Novo Nordisk has repurchased a total of 7,847,992 B shares at an average price of DKK 266.53 per share, for a total transaction value of DKK 2,091,696,255. Following these transactions, Novo Nordisk holds 25,237,791 B shares as treasury shares, equal to 0.6% of the 4,465,000,000 A and B shares outstanding, including treasury shares.
Novo Nordisk reports that the US FDA has approved Wegovy® HD, a once-weekly injectable semaglutide 7.2 mg dose, to reduce excess body weight and maintain long-term weight reduction. The FDA also granted a Commissioner’s National Priority Voucher, highlighting the therapy’s importance for US health priorities.
The accelerated approval is supported by the STEP UP phase 3 programme. In the STEP UP trial in adults with obesity, semaglutide 7.2 mg delivered a 20.7% mean weight loss, and 31.2% of participants achieved at least 25% weight loss. In the STEP UP T2D trial in adults with obesity and type 2 diabetes, mean weight loss reached 14.1%. Safety and tolerability were consistent with the known profile of semaglutide.
Novo Nordisk plans to launch Wegovy® HD in a single-dose pen in the US in April 2026. The 7.2 mg dose is already approved for adults with obesity in the EU and UK, and regulatory decisions on the single-dose pen in those regions are expected in the second half of 2026.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over the 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 March 2026, Novo Nordisk has repurchased 6,577,992 B shares at an average price of DKK 271.14, for a total of DKK 1,783,540,174. After these transactions, it holds 23,967,791 B shares as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports progress on its 2026 share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months from 4 February 2026, the company has been actively repurchasing shares in early March.
As of 6 March 2026, Novo Nordisk has repurchased 5,334,992 B shares at an average price of DKK 276.06, for a total of DKK 1,472,797,094. Following these transactions, it holds 22,724,791 B shares as treasury shares, equal to 0.5% of its total 4,465,000,000 A and B shares.
Novo Nordisk A/S reports that its employees have completed the election of new employee representatives to the company’s Board of Directors. These representatives are elected for a four-year term and, under Danish law, employee-elected members may make up half of the shareholder-elected board members.
The newly elected employee representatives will join the Board after the annual general meeting on 26 March 2026, when current employee board members Liselotte Hyveled and Tanja Villumsen, who did not run for re-election, will step down. Employee-elected directors have the same rights and responsibilities as shareholder-elected directors.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company is running an overall buyback of up to DKK 15 billion over 12 months beginning 4 February 2026, aimed at repurchasing B shares.
Under the specific programme running from 4 February 2026 to 4 May 2026, Novo Nordisk plans to buy back up to DKK 3.8 billion of B shares. As of 27 February 2026, it has repurchased 4,045,000 B shares at an average price of DKK 286.95, for a total of DKK 1,160,693,639.
Following these transactions, Novo Nordisk holds 21,434,799 B shares as treasury shares, representing 0.5% of its share capital. The company’s total share capital consists of 4,465,000,000 A and B shares, including treasury shares.
Novo Nordisk A/S is executing a share repurchase programme as part of an overall plan to buy back up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. A specific tranche targets up to DKK 3.8 billion of B shares from 4 February to 4 May 2026.
From 4 February to 20 February 2026, the company repurchased 2,750,000 B shares at an average price of DKK 306.18, for a total of DKK 841,997,435. After these transactions, Novo Nordisk holds 20,139,799 B shares of DKK 0.10 as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk reported headline phase 3 results from the REDEFINE 4 obesity trial comparing once-weekly CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg over 84 weeks in 809 people with obesity and comorbidities.
Using the efficacy estimand assuming full adherence, CagriSema led to 23.0% weight loss at 84 weeks versus 25.5% with tirzepatide. Under the treatment-regimen estimand, weight loss was 20.2% with CagriSema and 23.6% with tirzepatide. The primary endpoint of demonstrating non-inferiority of CagriSema to tirzepatide on weight loss was not achieved.
CagriSema showed a generally safe, well-tolerated profile with mostly mild to moderate gastrointestinal side effects that lessened over time. Novo Nordisk has submitted CagriSema for U.S. approval for weight management based on other pivotal trials, with an FDA decision anticipated by late 2026 and additional REDEFINE 11 and higher-dose CagriSema phase 3 readouts planned through 2027.
Novo Nordisk A/S has called its Annual General Meeting for 26 March 2026 at 14:00 (CET). The meeting will be held as a combined physical and virtual event, allowing shareholders to attend at Bella Center in Copenhagen or participate online by computer or mobile device.
Shareholders are encouraged to submit proxies or votes by correspondence in advance, with practical details provided in the accompanying meeting notice and via a live webcast. All shareholder-elected Board members are up for election, and the Board proposes re-electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and several other members, while nominating Helena Saxon, Jan van de Winkel and Ramona Sequeira as new Board members.